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xThyroid Hormone Regulation of Cholesterol Metabolism 
 
Lindsey R. Boone 
 
ABSTRACT 
 
 
 In this study, we examined the effects of thyroid hormone on regulatory 
processes of cholesterol metabolism.  Specifically, the pathways of cholesterol 
synthesis and cholesterol efflux were investigated.  Hepatic HMG-CoA reductase 
(HMGR) is the rate-limiting enzyme in cholesterol synthesis.  Hypothyroid rats 
exhibit decreased expression of this gene, which can be induced by subsequent 
treatment with thyroid hormone.  The mechanism of this activation was 
previously unknown.  Utilizing in vivo electroporation, we identified HMGR 
promoter elements necessary for the induction of HMGR by thyroid hormone.  
The -316/-321 element, the sterol response element, and nuclear factor-y site 
were all found to be necessary to induce HMGR promoter activity by thyroid 
hormone.  We used electrophoretic mobility shift assays (EMSA) and chromatin 
immunoprecipitation (ChIP) studies to demonstrate increased binding of 
upstream transcription factor-2 (USF-2) to the -316/-321 element in the HMGR 
promoter in response to thyroid hormone.  Finally, co-electroporation of the wild-
type HMGR plasmid with siRNA to USF-2, SREBP-2, or NF-Y nearly abolished 
the T3 induction as measured by promoter activity.  Microarray and real-time PCR 
analysis demonstrated an induction of the apolipoproteins ApoA-I and ApoA-IV 
xi
mRNA by T3.  Serum levels of ApoA-I and ApoA-IV proteins were induced by T3.  
We collected serum from rats treated with or without T3 and used these sera in 
an in vitro macrophage efflux model. We found that T3 promoted cholesterol 
efflux via the ABCA1 cholesterol transporter and not via the ABCG1 transporter.  
We propose that the induction of serum ApoA-I and ApoA-IV by thyroid hormone 
promotes cholesterol efflux via the ABCA1 cholesterol transporter.  Hepatic 
ABCG5 and ABCG8 are cholesterol transporters that promote biliary secretion of 
cholesterol.  We utilized EMSAs to scan the shared ABCG5/G8 rat promoter for a 
thyroid hormone response element (TRE).  We identified a TR binding site at -
392/-376 of the ABCG8 promoter.  Collectively, these observations provide new 
insight into the cholesterol-lowering function of thyroid hormone.    
1 
Chapter 1 
Introduction 
  
Cholesterol metabolism can be broadly viewed as the dietary intake or 
endogenous production of cholesterol and the subsequent utilization of this 
cholesterol in downstream processes such as cholesterol transport, cell 
membrane structure, bile acid production, and steroid hormone synthesis.  When 
exogenous cholesterol is ingested through the diet, it travels to the intestine 
where it is absorbed by enterocytes via the Niemann-Pick C1 Like 1 (NPC1L1) 
cholesterol transporter and packaged into lipid-rich chylomicrons (1, 2).  The 
chylomicrons are transported via the bloodstream and converted to chylomicron 
remnants that are cleared by the liver (3).  Once in the liver, the cholesterol can 
be repackaged into very low-density lipoproteins (VLDL) and secreted into the 
bloodstream (4) or oxidized into bile acids under the control of cholesterol 7 
alpha-hydroxylase (CYP7A1) (5).  Additionally, hepatic de novo cholesterol 
synthesis occurs under the control of HMG-CoA reductase (HMGR) and is the 
main source of cholesterol secreted from the liver (6).  VLDL secreted into the 
bloodstream contain triglycerides and cholesterol (7).  The VLDL particles unload 
triglycerides through interaction with lipoprotein lipase and become intermediate 
density lipoproteins (IDL) (8).  As the ratio of cholesterol to triglycerides becomes 
higher, the IDL particles become low density lipoproteins (LDL).  LDL particles 
bind the LDL receptor (LDLR) to unload cholesterol to peripheral tissues or clear 
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cholesterol from the bloodstream back into the liver (9).  In the presence of 
excess LDL cholesterol, deposition of cholesterol into the arterial lining can lead 
to atherosclerosis, which will be discussed in further detail in Chapter 3.   
High density lipoproteins (HDL) are the smallest and densest of the 
lipoproteins.  HDL are synthesized by the liver and secreted into the 
bloodstream.  Their main function is to transport cholesterol to steroidogenic 
organs and the liver.  They are capable of picking up cholesterol from the 
cholesterol transporter ATP-binding cassette transporter AI (ABCAI), in the 
process of cholesterol efflux from macrophages (10), an antiatherogenic process.  
The collected cholesterol, in the form of cholesteryl esters, can be removed from 
the HDL particle indirectly via exchange with the VLDL particle and uptake by the 
downstream LDL receptor (LDLR) or directly by the HDL receptor scavenger 
receptor BI (SR-BI) (11). 
Important components of the transport lipoproteins are the 
apolipoproteins.  Apolipoproteins are proteins that bind lipids to form lipoproteins.  
Apolipoprotein A-I is a major component of HDL and is a cofactor for lecithin 
cholesterolacyltransferase (LCAT), an enzyme that converts free cholesterol to 
cholesteryl ester (12).  Apolipoprotein B48 and B100 are essential components of 
VLDL, IDL, and LDL particles and act as ligands for the LDL receptor (13).  Also 
critical for cholesterol transport are the ATP-binding cassette transporters 
ABCA1/G1 and ABCG5/G8.  ABCA1 has been shown to regulate the process of 
excess cholesterol efflux from macrophages to the ApoA-I component of HDL 
3 
(14).  The ABCG5/G8 transporters function primarily in the intestine and liver and 
act to limit absorption of dietary cholesterol (15). 
Many of the genes involved in cholesterol metabolism are under 
cholesterol feedback regulation.  The sterol regulatory element-binding proteins 
(SREBP) are sterol-sensing transcription factors of the basic-loop-helix-leucine 
zipper (bHLH-Zip) family that activate cholesterolgenic genes when sterol levels 
are low (16).  SREBPs are membrane-bound and must be proteolytically cleaved 
to act (17).  When sterols are abundant, SREBPs are maintained in the 
endoplasmic reticulum by SREBP cleavage activating protein (SCAP) and insulin 
induced gene 1 (INSIG1) (18, 19).  When sterol levels drop, SCAP allows site-1 
cleavage to occur by Site-1 protease, which separates the functional domain of 
SREBP from the regulatory domain (17).  SREBP moves to the Golgi where site-
2 protease cleavage frees the NH2-terminal bHLH-Zip domain and allows for its 
transport to the nucleus for transcriptional regulation of target genes (20).  There 
are three known SREBPS: SREBP-1a and SREBP-1c are produced from a 
single gene and SREBP-2 is produced from a separate gene (20).  SREBP-1 has 
been shown to regulate genes involved in fatty acid metabolism while SREBP-2 
is known to regulate genes involved in cholesterol metabolism (21).               
Due to the necessity of cholesterol in physiological processes, 
modifications in its metabolism can have deleterious effects.  An important 
controller of cholesterol metabolism is thyroid hormone.  A low level of thyroid 
hormone is clinically diagnosed as hypothyroidism.  Patients with hypothyroidism 
exhibit hyperlipidemia (22) and are at an increased risk for cardiovascular 
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disease (23).  Treatment of hypothyroidism with thyroid hormone replacement 
therapy was shown to result in a less atherogenic lipid profile consisting of 
decreased plasma LDL cholesterol (24).  Data from an ongoing clinical trial of a 
thyroid hormone receptor agonist, MB07811, suggests lipid-lowering results in 
patients with mild hypercholesterolemia (25).  Also, the thyroid hormone mimetic, 
KB2115, was able to decrease LDL cholesterol levels and stimulate bile acid 
synthesis (26).  Thus, thyroid hormone is an important component in the field of 
cardiovascular disease. 
Thyroid hormone is produced by the follicular cells of the thyroid gland in 
response to thyroid stimulating hormone (TSH) released from the anterior 
pituitary.  Thyrotropin releasing hormone (TRH) from the hypothalamus 
stimulates release of TSH from the pituitary (27).  Thyroid hormone inhibits TSH 
and TRH release from the pitiuitary and hypothalamus as a negative feedback 
mechanism.  Two forms of thyroid hormone exist in the body: thyroxine (T4) and 
triiodothyronine (T3), which differ in iodine composition.  Thyroxine makes up the 
majority of thyroid hormone in the blood, has a longer half life than T3 and is less 
potent.  Thyroxine is converted to the biologically active form of thyroid hormone, 
T3, within target cells by deiodinases that remove an iodine molecule (28, 29).  
Most thyroid hormone in the blood circulates bound to thyroid binding globulin 
(TBG), while only the free form has hormonal activity.  Thyroid hormones 
functions mainly to increase metabolism, but also have roles in brain maturation 
during fetal development, regulation of long bone growth and sensitivity to 
catecholamines (30, 31). 
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The mechanisms of thyroid hormone’s effects on cholesterol metabolism 
have generally been well studied.  Thyroid hormone is known to activate a 
number of genes involved in cholesterol metabolism including the LDLR (32), the 
cholesterol transporter genes ATP-binding cassette G5/G8 (ABCG5/G8) (33), the 
rate-limiting enzyme in cholesterol biosynthesis HMGR (34), the rate-limiting 
enzyme in bile acid synthesis CYP7AI (35), and the apolipoproteins ApoA-I and 
ApoA-IV (36).  Physiological effects of thyroid hormone activation of these genes 
includes a decrease in circulating LDL cholesterol (37), a decrease in intestinal 
absorption of dietary cholesterol (33), and increased biliary cholesterol secretion 
(38).  Though clinical utilization of thyroid hormone in treating 
hypercholesterolemia is not as simple as administering T3 to patients, targeting 
thyroid hormone receptor-beta agonists to the liver has been shown to reduce 
cholesterol (39).      
Of the effects on gene expression, the mechanism of thyroid hormone 
activation of HMGR and the result of thyroid activation of ApoA-I and ApoA-IV 
have not yet been determined.  We utilized a hypophysectomized (Hx) Sprague-
Dawley rat model treated ± thyroid hormone to investigate these areas of 
cholesterol metabolism.  The Hx rax is surgically altered to be hypothyroid with 
the removal of its pituitary.  The absence of a pituitary gland prevents secretion 
of thyroid stimulating hormone (TSH) and its downstream control of thyroid 
hormone.  The hypothyroid Hx Sprague-Dawley rat demonstrates increased LDL 
cholesterol, which can be restored with thyroid hormone treatment (Fig. 1).  This 
effect mimics the effect of thyroid hormone on LDL cholesterol observed in 
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humans and provides a good mammalian model to study cholesterol metabolism.  
One caveat to this animal model is the disproportionate lipid profile relative to the 
human profile.  Humans maintain a greater proportion of total cholesterol in the 
LDL fraction whereas most cholesterol is found in the HDL fraction in rat serum 
(40).  However, the variations in relative proportions of cholesterol do not affect 
our studies.  Of note is the absence of a gallbladder in rats, the organ that stores 
bile.  The herbivorous nature of the rat does not require a large amount of bile to 
emulsify and absorb ingested animal fats.  The rat liver does produce bile, 
however, and the periportal plexus of bile ductules has been proposed as the bile 
storage organ (41). 
 
 
 
 
 
  
Figure 1.  Thyroid Hormone Decreases Serum LDL Cholesterol in Hypothyroid 
Rat.  Serum was collected from normal and hypophysectomized rats treated ±T3. 
Total serum serum LDL cholesterol is reported.  Data are reported as the mean ± 
standard error of the mean for each treatment.  Statistically significant differences 
are relative to Hx.  For all conditions, n4 and * p<0.05. 
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Chapter Two 
In vivo Identification of the Mechanism of Thyroid Hormone Activation of 
HMGR 
 
Introduction 
 
Cholesterol metabolism and serum cholesterol levels are profoundly 
affected by thyroid hormone (T3) status (42).  Key genes that are involved in 
regulating cholesterol metabolism include: LDL receptor, cholesterol 7 
hydroxylase and HMG-CoA reductase (HMGR) (43).  Each of these genes is 
regulated at the level of transcription by T3 (43).  Significant advances have been 
made in defining the mechanisms by which T3 regulates LDL receptor and 
cholesterol 7 hydroxylase (44, 45).  The promoter elements and transcription 
factors involved in T3 stimulation have been identified for these genes.  In 
contrast, the elements and transcription factors mediating T3 induction of HMGR 
have not yet been identified.   
HMGR is the enzyme that catalyzes the rate-limiting step in cholesterol 
biosynthesis.  HMGR is regulated by various mechanisms including hormonal 
(insulin, glucagon, thyroid hormone) and sterol (46-50).  Hepatic HMGR activity 
and gene expression is diminished in hypothyroid rats (50, 51).   Subsequent 
treatment with thyroid hormone (T3) restores HMGR mRNA, protein, and activity 
to levels actually greater than those observed in normal animals (50, 51).  
Notably, there is a considerable lag time for full induction of both mRNA and 
protein.  The greatest levels of induction are measured at 72 to 96 hours post-
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treatment, suggesting that the transcriptional response is not a direct effect. 
Rather it has been shown that both RNA and protein synthesis are required to 
achieve this T3-mediated induction (51).  
The mechanism of thyroid hormone activation of gene transcription has 
been well-studied.  Activation of gene transcription by T3 is usually mediated by 
thyroid hormone response elements (TRE), often of the DR4 type 
(AGGTCAnnnnAGGTCA). Typically in liver, the nuclear receptor thyroid receptor 
beta (TR-1) binds as a heterodimer with retinoic acid receptor (RXR-a) to 
induce gene transcription in response to T3 (52).  The long lag period for T3-
induction of hepatic HMGR suggests that T3 may act to increase expression of 
some other protein, which in turn would activate HMGR transcription through 
some element other than a TRE.  Also, the lack of a consensus TRE in the 
HMGR promoter required the consideration of non-traditional models of T3 
stimulation.     
Previous reports have identified upstream transcription factor-2 (USF-2), 
nuclear factor-Y (NF-Y), and the sterol regulatory element binding proteins 
(SREBP) as being necessary for the T3 response of other genes involved in 
metabolism (53-56).  USF-2 and NF-Y are ubiquitous transcription factors that 
function on a variety of genes (57, 58).  Though there has been no previous 
description of a USF-2 binding site in the HMGR promoter, an earlier report from 
our lab identified a NF-Y binding site in the proximal promoter of HMGR (59).  
The -316/-321 site in the rat HMGR promoter conforms to a DR4 half site 
9 
(AGGTCA).  Such a site was shown to mediate T3 induction of cholesterol 7 
hydroxylase (45).   
The HMGR promoter contains a sterol response element (SRE) to which 
SREBP-2 and SREBP-1 have been shown to bind (60, 61).  SREBP-1 and 
SREBP-2 are transcription factors that have been shown to function primarily on 
genes involved in cholesterol, fatty-acid, and triglyceride metabolism (46, 60, 62-
67).  The SREBP proteins typically interact with nearby transcription factors, such 
as NF-Y, to control gene transcription (66, 68, 69).  Previous work has shown 
that hypothyroid mice have decreased levels of mature SREBP-2 protein, which 
is induced by subsequent T3 treatment (70).  Interestingly, studies have shown 
that hypothyroid rats treated with either T3 or a combination of bile acid 
sequestrant and statin exhibit similar inductions of SREBP-2 and HMGR 
expression (70, 71), thus further linking SREBP-2 to T3 regulation of HMGR.  We 
hypothesized that the SREBP proteins may cooperate with additional 
transcription factors to mediate the T3 response.   
In this report, we utilized in vivo electroporation to characterize the 
promoter elements and factors necessary for T3 induction of HMGR gene 
expression.  Electroporation subjects membranes to a high-voltage electric field 
that results in the formation of pores that are large enough to allow DNA to enter 
the cell (72, 73).  In vivo electroporation allows for introduction of promoter-
luciferase constructs directly into the liver of live animals (74, 75).  A schematic of 
the electroporation process is presented in Figure 2.  In vivo electroporation 
results in transfection of hepatocytes within a well-defined region of the liver.  In 
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vivo imaging of electroporation of an HMGR-promoter luciferase construct 
demonstrates this precision (Fig. 3).  
The -325/+70 region of the HMGR promoter was determined to be 
sufficient for the full T3 response.  We showed that the transcription factor USF-2 
binds to the HMGR promoter in vivo and that USF-2 promoter binding is 
increased 4-fold by T3.  Furthermore, knockdown of USF-2, SREBP-2, and NF-Y 
by siRNA abolished the T3-mediated induction of HMGR gene expression as 
measured by promoter activity.  Thus, USF-2, SREBP-2, and NF-Y appear to 
play significant functional roles in mediating T3-induction of hepatic HMGR gene 
expression.  
Materials and Methods 
 
Plasmid Construction. The rat HMGR promoter was amplified to -5683 from a 
genomic BAC clone (CH230-263N2) from the rat genome using the Expand Long 
Template PCR System (Roche).  The -325/+70 HMGR promoter segments in 
pGL3-Basic (Promega, Madison, WI) were obtained as previously described (59).  
A -5123/+70 promoter fragment was obtained by using the primer sequences 
listed in Table 1.  This PCR product contains a NheI site at both ends for cloning.  
The -3187/+70 and the -2314/+70 promoter fragments were prepared from this 
large PCR product and cloned into pGL3-Basic vector using the restriction 
enzymes MluI and SacI, respectively.  All clones were confirmed by restriction 
analysis and DNA sequencing at the Moffitt Molecular Biology Core Facility 
(Tampa, FL). 
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Figure 2.  In Vivo Electroporation Process.  A, Liver is exposed; B, DNA is 
injected below the capsule; C, Electrode is placed over site of injection and voltage 
applied to introduce DNA into cell; D, Pattern of electrode remains for easy 
identification of site.   
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Figure 3.  In Vivo Imaging of in vivo electroporation.  Fifty mg of wild-type 
HMGR promoter plasmid was electroporated in the liver of a normal rat.  Imaging 
was performed 24 hours later using Xenogen in vivo Imager.   
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Experimental Animals.  Hypophysectomized and normal male Sprague-Dawley 
rats weighing 125 to 150 g were purchased from Harlan (Indianapolis, IN).  
Hypophysectomized rats received Tekland Iodine Deficient chow and water ad 
libitum and were housed in a reverse-cycle light controlled room with a 12-hour 
light period followed by a 12-hour dark period.  The rats were maintained on the 
Iodine deficient diet for 20 days prior to being used in experiments in order to 
achieve sufficient turnover of T4.  Rats on the iodine deficient diet were given an 
initial injection of 1.0 mg/kg T3 72 hours prior to electroporation and an additional 
injection of 0.25 mg/kg T3 24 hours prior to electroporation.  The rats were 
euthanized at the mid-dark period when hepatic HMG-CoA reductase expression 
is at its diurnal high, 24 hours following electroporation. 
 
Table 1.  Primer sequences used for cloning and site-directed mutagenesis. 
Target Sequence (5’3’) 
Plasmid  
CTGAAGCTATGCTAGCAGCTACAGAAATGGAGCGCTCTTC
G -5123/+70 
GAGAAGATGCTAGCATCTCAATGGAGGCCACCAAGC 
        
SDM        
CCGTGGTGAGAGATGTGTATTGTCCCGTTCTCCGCCCG 
SRE 
CGGGCGGAGAACGGGACAATACACATCTCTCACCACGG 
        
GCTCTTACGCGTCTGCCTTGACAATTCTGAGTTCGGGG 
USF-2 
CCCCGAACTCAGAATTGTCAAGGCAGACGCGTAAGAGC 
        
GCGGTGCCCGTTCTCCGAAATTTGTCGAGCAGTGGG 
SP-1 
CCCACTGCTCGACAAATTTCGGAGAACGGGCACCGC 
        
GGGCGACCGTTCGGTCATGCTTCCGTCAGGCTGAGCAG 
CRE 
CTGCTCAGCCTGACGGAAGCATGACCGAACGGTCGCCC 
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Electroporation Equipment.   An array of electrodes was used to administer 
porating direct current pulses (DC) to liver.  The electrode array was comprised 
of a cylindrical molded plastic handle with six 30 gauge acupuncture needles 
(NA2840, Suzhou Gusu Acupuncture & Moxitustion Appliance Co. Ltd., Japan) 
protruding from one end.  The needles were held in a fixed position at 60 degree 
intervals in a 0.5 cm diameter circle.  The needles extended 7 mm from the end 
of the handle.  The array was custom made at the University of South Florida 
along with an instrument system to supply voltage to the needles.  The 
instrument system consisted of a Dell Dimensions 8200 personal 
computer/monitor/keyboard, two mechanical relay boards (PCI-6521; National 
Instruments, Austin, TX), a DC power supply (9312-PS; Marlin P. Jones and 
Associates, Lake Park, FL), and LabVIEW software (National Instruments).  The 
LabVIEW software was used to write an application that utilized the computer 
and relay boards to direct the output from the power supply to the needles in a 
manner that rotated the applied voltage around the segment of liver delineated 
by the array.  A description of the pulsing order has been previously described 
(76).   
 
In Vivo Electroporation. Ten μg of HMG-CoA reductase promoter constructs and 
mutants ligated to luciferase were directly introduced into the livers of rats by 
electroporation as recently described (74) with minor modifications.  Renilla 
luciferase (Promega, Madison, WI) was co-electroporated at a 1:1000 dilution to 
control for electroporation efficiency.  The total volume of injected DNA was 50 
15 
μl.  The 5 mm diameter, six-needle electrode array was used to deliver 6 
rectangular DC electric pulses to the tissue.  Each pulse had a potential of 75 V 
and a duration of 150 ms. Pulses were administered with a 150 ms interval 
between them.  The voltage applied to the tissue corresponded to an electric field 
strength of 150 V/cm.  
 
Luciferase Assays.  Twenty-four hours following electroporation, the livers were 
harvested and tested for HMG-CoA reductase promoter activity by measuring 
luciferase activity.  Once removed, the electroporated regions of the liver were 
extracted using a 5 mm cork-borer.  Approximately 0.1 g of liver was placed in 
600 l of passive lysis buffer (Promega) and homogenized using a tissue 
disrupter.  The lysate was centrifuged at 16,000 g for 5 minutes and the 
supernatant assayed for luciferase activity using the dual luciferase assay kit 
from Promega.  Luciferase activity was calculated as the average ratio of firefly 
(reporter) to renilla luciferase for at least 2 injection sites per animal.       
 
Serum Preparation and Thyroid Hormone Assay.  Blood was collected from 
animals at time of euthanasia and centrifuged at 16,000 g for 5 min.  Supernatant 
(serum) was collected and used for determination of T3.  The T3 assay from 
Calbiotech (Spring Valley, CA) is a solid-phase competitive ELISA.  Free T3 in 
the serum competes with a T3 enzyme conjugate for binding to the anti-T3 
monoclonal antibody that coats the assay wells.   
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Site-Directed Mutagenesis. Mutant plasmids were produced using the 
QuikChange kit from Stratagene (Cedar Creek, TX).  The plasmid consisted of 
the double stranded DNA encoding the promoter with point mutations at the site 
of the SRE, USF-2 site, NF-Y site, CRE, or SP1-like site.  Primer sequences 
used are listed in Table 1.  The NF-Y mutant plasmid was previously prepared 
(59). 
 
Real Time PCR. Total RNA was isolated from rat livers using TRI Reagent 
(Molecular Research Center, Cincinnati, OH) and resuspended in nuclease-free 
water.  RNA was then DNAse treated using the TURBO DNA-Free Kit (Ambion, 
Austin, TX).  cDNA was prepared using the Reverse Transcription System 
(Promega) per the manufacturer’s protocol.  Primer sequences used are listed in 
Table 2.  mRNA was quantified under the following reaction conditions: 95oC for 
5 minutes, followed by 40 cycle of 95oC for 15 seconds, 61oC for 1 minute and 
melt curve 55oC + 0.5oC each 10 seconds, x 80.  All samples were run in 
duplicate on a Bio-Rad Chromo4 DNAEngine thermal cycler using SYBR green 
chemistry. Relative mRNA was calculated as a function of the internal control 18s 
using  Ct.   
 
Nuclear Extract.  Nuclei were prepared as previously described by centrifugation 
through dense sucrose (59).  Nuclei isolated from 2 g of rat liver were 
resuspended in 1 ml of PBS containing 3 mM MgCl2 and were centrifuged at 
3000 x g for 5 min at 4°C.  Nuclear pellets were resuspended in 300 L of high 
17 
salt buffer (420 mM NaCl, 20 mM HEPES, pH 7.9, 1 mM EDTA, 1 mM EGTA, 
20% glycerol, 20 mM NaF, 1 mM Na3VO4, 1 mM Na4P2O7, 1 mM dithiothreitol, 
0.5 mM phenylmethylsulfonyl fluoride, 1x protease inhibitor mixture (Sigma, St. 
Louis, MO).  Nuclei were lysed by rotating slowly at 4°C for 30 minutes.  The 
lysates were then centrifuged at 16,000 x g for 15 min to pellet nuclear debris.  
The supernatant (nuclear extract) was collected and protein concentrations 
determined using the BCA Assay from Pierce (Rockford, IL).    
 
Table 2.  Primer sequences used for qPCR.    
 
 
Target Sequence (5’3’) 
qPCR        
TGTGGGAACGGTGACACTTA    
HMGR 
CTTCAAATTTTGGGCACTCA    
        
GGATCATCCAGCAGCCTTTGA    
SREBP-2 
ACCGGGACCTGCTGCACCTGT    
        
CCCAGGATGTGCTTCAAACAGGAA   
USF-2 
TCCTTCTCCGCTCCACTTCATTGT    
        
AAGTTCAGAGAGGCCATGAAGGGA   
NFY-B 
TCTGCAGTTATTAACCCAGCCGGT   
        
CCATCCAATCGGTAGTAGCG    
18s 
GTAACCCGTTGAACCCCATT    
        
ChIP qPCR        
CCACACTCCAACTCTGACACGGT   
USF-2 
CCGAGCCAACCAATGGCTAGT    
        
ACTAGCCATTGGTTGGCTCGG    
SREBP1/2,NFY 
CGCCAATAAGGAAGGATCGTCCGAT   
        
18 
EMSA.  Electrophoretic mobility shift assays were performed as previously 
described (59).  Briefly, probes corresponding to the wild type (Wt) SRE and 
mutant (Mt) SRE were generated by annealing two complementary 
oligonucleotides (Integrated DNA Technologies).  Oligonucleotide sequences are 
listed in Table 3.  One pmol of probe was labeled by the Klenow fill-in reaction 
using 20 Ci of [-32P] dCTP along with cold 0.125 mM dATP, dGTP, and dTTP.  
Each probe (25 fmol) was incubated with 2.0 g of rat liver nuclear extract protein 
in binding buffer (10 mM HEPES, pH 7.9, 25 mM KCl, 0.5 mM EDTA, 50 g/ml 
poly(dI-dC), 5% glycerol, 0.5 mM DTT, 125 g/ml bovine serum albumin) for 30 
minutes at room temperature. Binding reactions were run on a 6% 
polyacrylamide gel in 0.25x TBE.  For antibody supershift experiments, binding 
reactions were incubated with 1-3 μg of antisera for 30 minutes prior to the 
addition of probe.  The antibodies were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA): PPAR (sc-9000x), tr-1 (sc-772x), USF2 (sc-
862x), SF1 (sc-28740x), ESR1 (sc-542x), RXRa (sc-553x), C/EBPa (sc-9314x), 
USF1 (sc-8983x), USF2 (sc-861x), C/EBP (sc-746x), Sp1 (sc-17824x), HSTF1 
(sc-9144x), ATF2 (sc-187), E4BP4 (sc-9550), SHP (sc-15283), FTF/LRH1 (sc-
5995x), and NFY (sc-7711x).   
 
Chromatin Immunoprecipitation. Chromatin was prepared and 
immunoprecipitated using the ChIP-IT Express kit from Active Motif (Carlsbad, 
CA).  The protocol was modified for liver tissue preparation.  All named buffers 
are included in the kit.  Equal portions of liver (100 mg total) from 3 rats per 
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treatment group (±T3) were minced and fixed in 1% formaldehyde for 5 minutes 
at room temperature.  One mL of Glycine Stop-Fix Solution was added to stop 
fixation and incubated for 5 minutes.  Samples were centrifuged for 5 minutes at 
720g.  The pellets were resuspended in 6 ml scraping solution and centrifuged at 
720g for 5 min.  The pellets were resuspended in 1.5 ml ice-cold Lysis Buffer 
supplemented with 7.5 μl protease inhibitors (PIC) and 7.5 μl PMSF and 
incubated on ice for 30 minutes.  The tissue was homogenized in a Dounce 
homogenizer for 10 strokes on ice to release the nuclei.  The homogenates were 
then centrifuged at 2400g for 10 min at 4oC to pellet the nuclei.  The nuclei were 
resuspended in 1 ml of Complete Shearing Buffer supplemented with 5 μl PIC 
and disrupted using an Ultrasonic model W-375 sonicator at 40% duty cycle and 
output control at 3.  Sonication was applied 5 times each for 15 seconds on, 30 
seconds off, to shear chromatin.  Chromatin size was checked by agarose 
electrophoresis to ensure an average size between 200 and 500 bp.  Chromatin 
was precleared with 35 μl of magnetic beads per 500 μl chromatin by rotating at 
4oC for 30 minutes and collected.  Eighty μl of chromatin, 3 μg of antibody, and 
25 μl of beads were used for each IP reaction.  The antibodies used were: 
SREBP-2 (Cayman Chemical, #10007663), USF-2 (SCBT, sc-861x), SREBP-1 
(SCBT, sc-8984x), NF-Y (SCBT, sc-13045x), and RXR- (SCBT, sc-553x).  The 
negative and positive control antibodies were part of the ChIP-IT Kit.  The 
reactions were rotated at 4oC with antibody for 17 hours.  Final DNA samples 
were analyzed by qPCR in triplicate as described above.  The relative level of 
transcription factor binding was quantified by correcting for amount of input DNA 
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and negative control antibody DNA (background), which were performed in 
parallel.  Relative induction of binding was calculated as the ratio of relative 
binding of the factor in the Hx +T3 chromatin preparation to the relative binding of 
the factor in the Hx chromatin preparation.  The data are the results of at least 3 
independent immunoprecipitation experiments on pooled chromatin samples.  
PCR products from ChIPs performed with antibodies to USF-2 and NF-Y were 
also run on a 2% agarose gel to show in vivo binding of these factors.  PCR was 
carried out as described under real-time PCR methods above with the omission 
of a melt curve. 
 
Table 3.  Primer sequences used for EMSA probes. 
 
 
Target Sequence (5’3’) 
  
TGGTGAGAGATGGTGCGGTGCCCGTTCTCCG 
WT SRE 
CGATCGGAGAACGGGCACCGCACCATCTCTCACCA 
        
TGGTGAGAGATGTGTATTGTCCCGTTCTCCG 
MT SRE 
CGATCGGAGAACGGGACAATACACATCTCTCACCA 
        
GGAAACACCCTGCAGGTCAAATTCTGAGTTCGGGGTACT 
WT USF2 
CGATGAACTCAGAATTTGACCTGCAGGGTGTTTCC 
        
GGAAACACCCTGCCTTGACAATTCTGAGTTC 
MT USF2 
CGATGAACTCAGAATTGTCAAGGCAGGGTGTTTCC 
        
GCCTCCCGCCGATTGGCTAGGGGATCGGAC 
WT NF-Y 
CGATGTCCGATCCCCTAGCCAATCGGCGGGAGGC 
        
GCCTCCCGCCGCGGTTCTAGGGGATCGGAC 
MT NF-Y 
CGATGTCCGATCCCCTAGAACCGCGGCGGGAGGC 
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siRNA Knockdown Study.  Following the treatments described previously under 
Experimental Animals, 5 μg of SREBP-2 siRNA (Dharmacon cat# L-081475-01), 
or 20 μg of USF-2 siRNA (SABiosciences cat# SIR449799A-C), or NFY siRNA 
(SABiosciences cat# SIR252807A-C) was co-electroporated with or without 10 
μg -325/+70 HMGR promoter construct in a final volume of 50 μl using at least 2 
sites per animal.  The electroporated sites were removed 24 hours later using a 5 
mm cork-borer.  For NF-Y experiments, samples were also removed after 48 hrs. 
Luciferase assays were performed as described above.  qPCR was performed to 
measure knock down of endogenous USF-2, SREBP-2, or NFY mRNA.  Five μg 
of Dharmacon cat# L-096650-01 siRNA was used as the negative control, as 
electroporation of this siRNA did not knockdown the target gene. 
 
Statistical Analyses.  Data is expressed as the mean +/- standard error for a 
minimum of 3 animals per group.  Experimental treatments included 
hypophysectomized Sprague-Dawley and hypophysectomized Sprague-Dawley 
rats treated with T3. 
Results 
Functional Analysis of the HMGR Promoter 
We utilized in vivo electroporation in a hypothyroid (Hx) rat model to 
analyze the regulatory mechanism of T3 induced hepatic HMGR gene 
expression.  Hx rats were treated ± T3 96 hours before harvest of liver tissue to 
measure hepatic HMGR gene expression by real-time PCR.  HMGR gene 
expression was induced approximately 2.7-fold by thyroid hormone (Fig. 4A).  In 
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order to define the region of the HMGR promoter necessary for this induction, 
four promoter-luciferase constructs inclusive of the HMGR promoter from -5683, -
3190, -2314, or -325 to +70 bp were generated.  The plasmids were 
electroporated into the livers of Hx rats treated ±T3.  We found that the -325/+70 
region was sufficient to induce maximum thyroid hormone stimulation of HMGR 
promoter activity (Fig. 4B).  With this construct, a 2.5-fold induction of HMGR 
promoter activity was observed in response to T3, which correlates well with the 
increase observed in mRNA levels.  
The -325/+70 region of the promoter is highly conserved in mammalian 
species (Fig. 5).  Specifically, the -316/-321 element, the sterol response element 
(SRE), and the NF-Y binding sites all lie within regions of very high conservation 
in the HMGR promoter.  The element at -316/-321 is a conserved element that 
serves as a near-consensus binding sequence for a TRE half-site, the USF-2 
transcription factor (57), as well as other common transcription factors (77-79).  
USF-2, SREBP-2, and NF-Y have previously been shown to function in T3 
regulation of genes such as fatty acid synthase, S14, and carnitine 
palmitoyltransferase-I (53-55).  Thus, we hypothesized that T3 induction could 
occur through these sites.   
In an effort to identify the factor that binds to the -316/-321 region, we 
performed EMSAs.  Figure 6 shows an experiment in which a Wt probe to the -
316/-321 region was incubated in a binding reaction with normal rat liver nuclear 
extract.  An unlabeled double-stranded oligonucleotide corresponding to the 
exact sequence of the Wt with the exception of single nucleotide substitutions 
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was added in 50x molar excess relative to the radiolabeled probe in the 
remaining lanes. The sequence at the top of the figure is the wild type promoter 
sequence, with an arrow highlighting the nucleotide substitution in each lane. The 
Wt band in Fig. 6 can be efficiently competed away with the cold wild-type 
competitor (2nd lane).  The mutants that were unable to compete away the wild-
type binding represent the sequence AGGTCAAA_TCTG.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Thyroid Hormone Induces Hepatic HMGR.  A, Real-time PCR analysis of 
total HMGR mRNA isolated from livers of hypophysectomized rats treated ± T3.  B, An 
HMGR promoter construct inclusive of the -325/+70 region was electroporated into the 
livers of hypophysectomized rats treated ±T3.  Data are reported as the mean ± 
standard error of the mean for each promoter construct.  Statistically significant 
differences are relative to Hx with wild-type construct. For all conditions, n4 and 
*p<0.05. 
24 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
We prepared plasmids inclusive of the -325/+70 promoter region (Wt) with 
point mutations in each of these elements as well as the Sp1-like site at -145/-
138 and the cAMP response element at -104/-97.  The mutated plasmids were 
then introduced into the livers of Hx rats treated ±T3 as described previously.  
Independent mutations in the -316/-321 element, SRE, and NFY binding site 
resulted in essentially complete loss of the T3 induction (Fig. 7).  These data 
Figure 5.  -316/-321, SRE, and NF-Y Promoter Elements are Highly Conserved 
across Species.  Multiple sequence alignment was performed using the 
CLUSTALW2 tool provided by EMBL-EBI.  HMGR promoter sequences for H. 
sapiens, R. norvegicus, and M. musculus were obtained from GenBank.  
Nucleotides are labeled ± from the transcription start site.   
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suggest that all three elements and their respective transcription factors are 
necessary for T3-mediated induction of HMGR transcription. Mutations in the 
SP1-like site and CRE did not abolish the T3 response of the HMGR promoter 
(data not shown).   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.  EMSA Analysis of the -325/-307 HMGR Promoter Region.  EMSA of 
single point mutations in the -325/-307 region.  50x competitor probes were used to 
identify nucleotides that are necessary for binding to occur to the -316/-321 
element. The wild-type promoter sequence is listed on top with an arrow pointing to 
the point mutation in the competitor probe.  
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Binding of USF-2 to the HMGR Promoter 
We used the online transcription factor prediction program PROMO to identify 
a number of potential factors that could bind the -316/-321 sequence (80).  We 
used nuclear extract prepared from normal rats to perform EMSA antibody 
supershift experiments with antisera to the transcription factor candidates (Fig. 
8).  Antisera for RXR  and USF-2 produced shifted bands.  Interestingly, the 
TR-1 antisera did not produce a supershift.  The USF-2 antibody (sc-861) 
Figure 7.  -316/-321, SRE, and NF-Y Promoter Elements are Necessary for the 
Thyroid Hormone Response.  HMGR promoter construct spanning the -325/+70 
region (wild-type) as well as constructs with mutations in the -316/-321, SRE, or NF-
Y binding sites were electroporated into the livers of hypophysectomized rats 
treated ±T3 (n4).  Data are reported as the mean ± standard error of the mean for 
each promoter construct.  Statistically significant differences are relative to Hx with 
wild-type construct.  *p<0.05       
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produced a shifted band, while the USF-2 antibody (sc-862) did not.  The USF-2 
(sc-862) antibody recognizes the C-terminus of USF-2, which functions as the 
DNA-binding component of the protein, thus preventing the binding of the 
antibody.   
To confirm the binding of USF-2 to the HMGR promoter in vivo, ChIP 
analysis was performed on pooled chromatin samples prepared from the livers of 
Hx + T3 rats.  PCR was performed on the immunoprecipitated DNA and products 
were run on agarose gels for identification.  USF-2 was found to bind the HMGR 
promoter in vivo (Fig. 9).  This is the first report of in vivo evidence showing USF-
2 binding to the HMGR promoter at -316/-321.  Chromatin was then prepared in 
two pools of 3 equal amounts of liver from Hx rats treated ±T3.  ChIP assays 
were performed and immunoprecipitated DNA analyzed using qPCR to measure 
the induction of transcription factor binding to the HMGR promoter in response to 
T3.  Most notably, USF-2 binding was induced approximately 4-fold in response 
to T3 (Fig. 10).  The binding of SREBP-2 or NF-Y was not significantly increased 
in response to T3 treatment.   
 
siRNA Knockdown of Transcription Factors 
In order to better understand the functional necessity of the USF-2, NF-Y, 
and SREBP-2 transcription factors in the T3 induction of HMGR transcription, we 
performed in vivo siRNA knockdown assays.  We hypothesized that knockdown 
of these necessary factors would mimic the results of our previous mutations in 
the HMGR promoter elements and abolish the T3 response as measured by 
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HMGR promoter activity. In order to determine if siRNA knockdown could be 
utilized to analyze the functional role of the identified transcription factors, we 
measured the levels of mRNA for SREBP-2, SREBP-1, USF-2, and NF-Y in 
response to T3 treatment (Fig. 11).  We observed a 1.5-fold induction of SREBP-
2 mRNA in response to T3 treatment, which correlates with previous reports that 
SREBP-2 mRNA is transcribed and protein translated in response to T3 treatment 
(70).  This narrow effect may be sufficient to drive T3 induction of HMGR 
transcription, as previous studies have shown tight control of SREBP processing 
(81).  This mechanism is consistent with the long lag period for induction of 
HMGR and suggests that knockdown of SREBP-2 may decrease induction of 
HMGR by T3.     
  USF-2, SREBP-1, and NF-Y mRNAs were unchanged in response to T3.  
USF-2 and NF-Y are ubiquitously expressed and function as transcription factors 
for a number of unrelated genes (57, 58), which suggests that they may be less 
sensitive to hormonal stimuli.  The SREBP proteins are more specialized and 
function primarily on genes involved in fatty-acid and lipid metabolism (65), which 
themselves are frequently T3 responsive (53, 70) 
siRNA to USF-2, SREBP-2, or NF-Y was electroporated into the livers of 
Hx + T3 rats.  Efficacy of siRNA knockdown was measured by qPCR analysis of 
endogenous mRNA isolated from individual electroporation sites 24 hours 
following electroporation.  siRNA treatment resulted in maximal knockdown of 
endogenous USF-2 to 82% of control and SREBP-2 to 51% of control (Fig. 12) 
within 24 hours.  siRNA to NF-Y required a greater period of time to achieve 
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optimal knockdown, with knockdown to 79% of control achieved at 24 hours and 
to 24% of control at 48 hours. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.  EMSA Analysis of the -316/-321 HMGR Promoter Region.  A probe 
corresponding to the -325/-307 promoter region was incubated with 2 μg of pooled 
nuclear extract prepared from the livers of normal rats.  A. Three μg of antibody to 
potential transcription factors was added to each binding reaction to obtain a 
supershift of the protein-probe complex. B. Lane 1 shows binding reaction.  Lanes 
2-7 show the addition of increasing amounts of USF-2 antibody (1-6 μg). 
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Having generated a considerable knockdown of endogenous mRNA, we 
then co-electroporated the Wt HMGR plasmid with siRNA to each factor.  siRNA 
to USF-2 and SREBP-2 generated knockdown of HMGR promoter activity to 
49% or 44% of control, respectively and essentially abolished the T3 response 
(Fig. 12).  This knockdown is consistent with the difference in Wt HMGR 
promoter activity observed in the Hx rat compared to rats treated with T3 (Fig. 
4B).  Electroporation of NF-Y siRNA resulted in knockdown of HMGR promoter 
activity that was highest after 48 hours.  The knockdown at 24 hours was to 75% 
of control compared to 57% of control at 48 hours (Fig. 12).  These in vivo 
knockdown assays indicate functional roles for USF-2, SREBP-2, and NFY in T3 
activation of HMGR transcription. 
Figure 9.  USF-2 Binds to the HMGR Promoter.  ChIP assays were performed on 
pooled chromatin prepared from equal portions of liver collected from 3 Hx + T3 
rats.  Sheared chromatin was immunoprecipitated using the antibodies indicated. 
Immunoprecipitated DNA was analyzed by PCR and products (220bp) were run on 
a 2% agarose.  
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Discussion 
 
We utilized in vivo electroporation in a hypothyroid rat model to analyze 
the regulatory mechanism of T3 induced hepatic HMGR gene expression.  
Though the effect of T3 on HMGR transcription has been well documented (51, 
71, 82, 83), little is known about the actual molecular mechanism responsible for 
this regulation.  Due to the significant lag time required for induction of HMGR 
following T3 treatment and the necessity of mRNA and protein synthesis to 
Figure 10. USF-2 Binding to the HMGR Promoter is Increased 4-fold in 
Response to T3.  Two chromatin pools were prepared from equal portions of liver 
collected from 3 rats in each treatment group (±T3).  ChIP was performed for the 
transcription factors listed.  Immunoprecipitated DNA was analyzed by qPCR in 
triplicate.  Fold-change in binding was calculated for at least three separate ChIP 
experiments as the ratio of Hx + T3 binding to Hx binding.  Statistically significant 
differences are relative to the total input DNA set at 1.  *p<0.05    
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produce the response (51), we hypothesized that an atypical mechanism may be 
involved in transcriptional activation.  Furthermore, the lack of a consensus TRE 
in the HMGR promoter suggests that T3 induction occurs via another mechanism.  
Though we were unable to locate a TRE in the proximal promoter, it may be 
worthwhile to search intronic sequences for a TRE, as this has been documented 
for the carnitine palmitoyltransferase-I alpha gene (54).      
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 11.  Real-time PCR Analysis of the Effect of Thyroid Hormone on 
Transcription Factors that Bind the HMGR Promoter.  Total RNA was isolated 
from livers of hypophysectomized rats treated ± T3 (n4).  Quantitative real-time 
PCR was performed to measure relative mRNA levels of USF-2, SREBP-2, NF-Y, 
and SREBP-1.  Statistically significant differences are relative to Hx mRNA for each 
gene. *p<0.05 
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We measured a 2.5-fold induction of HMGR promoter activity with a Wt 
plasmid corresponding to the -325/+70 region of the HMGR promoter.  This value 
agrees well with the 2.7-fold induction of HMGR mRNA as measured by qPCR.  
Analysis of the HMGR promoter out to -5683 bp resulted in no additional 
increase in HMGR promoter activity.  The -325/+70 region of the promoter is 
highly conserved in mammalian species.  Specifically, the USF-2, the SRE, and 
the NF-Y binding sites all lie within regions of high conservation in the HMGR 
promoter.  This suggests that the mechanism of T3 induction could likely occur 
through these sites.  Also, each of these factors have previously been shown to 
function in the T3 regulation of genes such as fatty acid synthase, S14, carnitine 
Figure 12.  In Vivo siRNA Knockdown of Hepatic USF-2, SREBP-2, and NF-Y. 
Total RNA was isolated from the livers of hypophysectomized rats treated with T3 
and electroporated with 5 μg SREBP-2, 20 μg USF-2 or NF-Y siRNA, or saline 
control (n3).  qPCR was performed to measure relative endogenous mRNA levels 
of each factor in response to the respective siRNA.  Saline electroporation was set 
to 100% as the control for each gene.  siRNA knockdowns are presented as a 
percentage of this control.   
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palmitoyltransferase-I, acetyl-CoA carboxylase-alpha, and ApoA-V (53-55, 84).  
Correspondingly, mutations in each of these elements resulted in essentially 
complete loss of T3 induction as measured by HMGR promoter activity.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The binding of SREBP-1 and SREBP-2 to the HMGR promoter is well 
established in the literature (60, 61) and in vitro and iv vivo assays have shown 
NF-Y to bind the -65/-69 element (59, 61).  However, there has been no report of 
Figure 13.  In Vivo siRNA Knockdown Demonstrates the Functional roles of 
USF-2, SREBP-2, and NF-Y on Hepatic HMGR Promoter Activity.  An HMGR 
promoter construct spanning the -325/+70 region (wild-type) and either 5 μg 
SREBP-2 or 20 μg USF-2 or NF-Y siRNA were co-electroporated into the livers of 
hypophysectomized rats treated with T3.  Wild-type promoter activity was set to 
100% as the control.  siRNA knockdowns are presented as a percentage of this 
control.  Data are reported as the mean ± standard error of the mean for each 
treatment.  Statistically significant differences are relative to control (n3).  * p<0.05, 
† p<0.10 
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USF-2 binding to the -316/-321 element.  Here we present data that provides in 
vivo evidence of USF-2 binding to the HMGR promoter.  A previous report has 
shown this sequence to bind the LRH-1/FTF protein to mediate bile acid 
regulation of HMGR, though we were unable to replicate this binding by EMSA 
(85).  It is not unusual for USF-2 to regulate genes involved in lipid metabolism, 
as it has been identified as a regulator of Apolipoprotein A5 (84) and is 
associated with familial combined hyperlipidemia (86).   
ChIP analyses of a number of transcription factors show that USF-2 
promoter binding is increased 4-fold with T3 treatment.  It is possible that 
although USF-2 is bound to the promoter in a basal state, additional USF-2 
protein is recruited to the HMGR promoter in response to T3.  USF-2 is a member 
of the evolutionary conserved basic-helix-loop-helix-leucine zipper transcription 
factor family (57) that functions as a homodimer or heterodimer with USF-1.  The 
USF proteins function in transcriptional activation via a number of pathways 
including cooperative interaction with other factors (87), homo- and 
heterodimerization and DNA looping (88), and the recruitment of histone 
modifications (89).  The most likely mechanism is the absence of USF-2 from the 
Hx HMGR promoter and the subsequent recruitment of a USF-2 dimer or 
tetramer in response to T3.  The binding of other factors assayed was not greatly 
increased in response to T3 treatment, suggesting that they may be required for 
basal regulation of the gene, and while not solely responsible for the induction of 
HMGR transcription, are indeed necessary.  
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In order to better understand the functional necessity of the USF-2, NF-Y, 
and SREBP transcription factors in the T3 response of HMGR transcription, we 
measured their gene expression in response to T3.  Real-time PCR analysis of 
SREBP-2 showed that SREBP-2 mRNA was modestly induced by T3 treatment 
suggesting that knock down of this target may decrease the induction of HMGR 
by T3.  This narrow effect may be sufficient to drive T3 induction of HMGR 
transcription, as previous studies have shown tight control of SREBP processing 
(81).  Real-time PCR analyses of USF-2 and NF-Y did not show an induction of 
the mRNA for these genes in response to T3 treatment.  These factors are 
ubiquitously expressed and function as transcription factors for a number of 
unrelated genes (57, 58), which implies that they may be less sensitive to 
hormonal stimuli.  The SREBP proteins are more specialized and function 
primarily on genes involved in fatty-acid and lipid metabolism (63-66), which 
themselves are frequently T3 responsive (53, 70, 90).   
We hypothesized that knockdown of these necessary factors would mimic 
the results of our previous mutations in the HMGR promoter elements and 
abolish the T3 response as measured by HMGR promoter activity.  We performed 
in vivo siRNA experiments using the On-TARGETplus SMARTpool siRNAs from 
Dharmacon or SureSilencing siRNA from SABiosciences.  These pools contain 
four duplexes all designed to target distinct sites within the specific gene of 
interest, providing high efficiency of knockdown.  Following successful 
knockdown of endogenous targets, we then co-electroporated the Wt HMGR 
plasmid with siRNA to each factor.  siRNA to USF-2, SREBP-2, and NF-Y 
37 
essentially abolished the T3 response.  This knockdown is consistent with the 
difference in Wt HMGR promoter activity observed in the Hx rat compared to rats 
treated with T3.  It is pertinent to note that quantification of endogenous mRNA 
knockdown (Fig. 12) may include hepatocytes that were not transfected with 
siRNA due to the potential collection of extraneous tissue.  This may result in 
masking of the knockdown effect.  In contrast, knockdown of HMGR promoter 
activity (Fig. 13) is measured by luciferase assay, which only quantifies 
successfully transfected cells.  Thus, discrepancies in relative knockdown 
between endogenous mRNA and promoter activity are expected.                    
      In conclusion, the -325/+70 region of the HMGR promoter appears 
sufficient for the full T3 response.  The newly described element at -316/-321 was 
shown to bind USF-2 in vivo.  Binding of USF-2 to this element was markedly 
increased by T3 treatment.  The transcription factors USF-2, SREBP-2, and NF-Y 
are necessary for the response, as mutations in the elements binding these 
factors markedly diminished the T3 response.  Furthermore, knockdown of USF-
2, SREBP-2, or NF-Y mRNA was able to nearly eliminate the T3 response, which 
suggests functional roles for all of these factors in regulating hepatic HMGR 
promoter activity.  Even though T3 did not appear to cause significant increases 
in binding of SREBP-2 or NF-Y to the HMGR promoter, the decreases observed 
after siRNA treatment indicate that these factors are also required.  Together, 
these data provide a working model for T3 induction of HMGR gene expression.   
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Chapter 3 
Thyroid Hormone Promotes Macrophage Cholesterol Efflux via ABCA1 
 
Introduction 
 
The deposition of excess cholesterol into the arterial lining and 
subsequent hardening of the arteries is the well-known condition of 
atherosclerosis.  In this disease, circulating plasma LDL particles invade the 
endothelium and become oxidized (91).  The body’s inflammatory response 
sends monocytes to the site of invasion that differentiate into macrophages (92).  
These macrophages phagocytose the oxidized LDL and are transformed into 
foam cells, which are retained in the endothelial wall (93).  The accumulation of 
foam cells leads to the formation of lesions in the arteries known as fatty streaks 
(94).  These are the first steps of atherosclerosis and are naturally occurring 
processes that are result from high levels of LDL cholesterol (95).   
The cholesterol transport mechanism that opposes this lipid deposition is 
reverse cholesterol transport (RCT), or cholesterol efflux.  RCT is a protective 
mechanism that lessens the cholesterol burden in atherosclerotic plaques.  This 
process is mediated by lipid-poor circulating plasma HDL particles.  HDL 
particles are synthesized by the liver and secreted into the bloodstream.  It has 
been proposed that through interaction with hepatic ABCAI, the particles are 
fitted with two to four molecules of ApoA-I (96, 97).  These lipid-poor particles are 
designated pre-beta HDL (98).  In RCT, pre-beta HDL particles composed 
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primarily of nascent ApoA-I dock onto the cholesterol transporter ABCAI found in 
cholesterol-laden macrophages (99).  The ApoA-I c-terminal domain has been 
shown to be necessary for cell-surface binding and cholesterol efflux from 
macrophages (100).  This interaction allows for lipidation of ApoAI (10) via 
ABCAI and its subsequent transformation to a lipid-enriched particle (101, 102).  
The cholesterol transporter ABCG1 has also been implicated in cholesterol efflux 
to HDL (103, 104), however ABCA1 was shown to export cholesterol and 
phospholipid to lipid-free apolipoproteins, while ABCG1 exports cholesterol to 
phospholipid-containing acceptors and not necessarily apolipoproteins (105).  
The pre-beta HDL particles become alpha-HDL particles as they circulate 
through the bloodstream and collect cholesterol, a process mediated by 
phospholipid transfer protein (PLTP) and cholesteryl ester transfer protein 
(CETP) (106). 
Given the ability of HDL to facilitate the efflux of cholesterol from 
macrophages, it is not surprising that increased serum HDL cholesterol 
correlates with decreased levels of atherosclerosis (107).  This may be due to 
higher levels of ApoA-I, the cholesterol acceptor on HDL.  Treatments with ApoA-
I mimetics have been shown to increase the formation of pre-beta high-density 
lipoprotein, increase cholesterol efflux, and reduce lipoprotein oxidation in vitro 
and improve HDL inflammatory properties in humans with coronary heart disease 
(108).    
Apolipoprotein A-IV is a lesser studied apolipoprotein component of HDL.  
But like ApoA-I, ApoA-IV has been shown to remove cholesterol from fibroblast 
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cells (109), mediate efflux via the ABCA1 transporter (110), and activate LCAT 
(111).  Additionally, it has been found to bind hepatocellular plasma membranes 
(112).  This effect may have important clinical implications, as ApoA-IV functions 
as a ligand for HDL to bind a hepatic receptor site distinct from apoE-dependent 
receptors (113). 
Previous reports have identified the activation of hepatic ApoA-I and Apo-
IV by thyroid hormone.  While little is known about the effect of this regulation, 
thyroid hormone was shown to stabilize ApoA-IV mRNA (114).  It is presently not 
known whether thyroid hormone acts to increase the cholesterol efflux from cells 
to acceptor HDL.  In this study, we investigated the ability of serum from 
hypothyroid rats treated ± thyroid hormone to stimulate cellular cholesterol efflux 
via ABCA1 or ABCG1.  Furthermore, we examined the effect of thyroid hormone 
on serum lipoproteins. 
Materials and Methods 
 
Experimental Animals.  Hypophysectomized and normal male Sprague-Dawley 
rats weighing 125 to 150 g were purchased from Harlan (Indianapolis, IN).  
Hypophysectomized rats received Tekland Iodine Deficient chow and water ad 
libitum and were housed in a reverse-cycle light controlled room with a 12-hour 
light period followed by a 12-hour dark period.  The rats were maintained on the 
Iodine deficient diet for at least 21 days prior to being used in experiments in 
order to achieve sufficient turnover of T4.  Rats on the iodine deficient diet were 
given an initial injection of 1.0 mg/kg T3 72 hours prior to harvest of tissue and an 
additional injection of 0.25 mg/kg T3 24 hours prior to harvest of tissue.   
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HDL and T3 Assays.  Blood was collected and centrifuged at 16,000 x g for 5 
min.  The supernatant (serum) was collected and used for determinations of 
HDL, apolipoproteins and T3.  HDL levels were measured using the HDL and 
LDL/VLDL Cholesterol Quantification Kit from BioVision (Cat# K613-100; 
Mountain View, CA).  T3 levels were measured using the Free T3 ELISA from 
Calbiotech (Cat# F3106T; Spring Valley, CA)   
 
RNA Isolation. A portion of about 200 mg was quickly excised from the livers of 
the rats and immediately homogenized in 4 ml of Tri-Reagent from Molecular 
Research Center (Cincinnati, OH) using a Polytron homogenizer at room 
temperature.  Aortas were removed from the diaphragm to the bifurcation of the 
iliac arteries.  The remainder of the isolation steps was carried out using volumes 
corresponding to 4x the manufacturer’s recommendations.  RNA concentrations 
were determined by diluting each sample 1:100 and measuring their absorbance 
at 260nm. 
 
Microarray Analysis. Isolated RNA was further purified using the RNeasy kit from 
Qiagen.  To demonstrate that the RNA was indeed free of RNase activity, 
samples were incubated in water at 42º C for 1 hr and then examined on 1% 
agarose gels.  An identical pattern of bands in unheated and heated samples 
was obtained showing a lack of RNase activity.  Microarray analysis was 
performed by the Moffitt Core Facility (Tampa, FL) using the Affymetrix 
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GeneChip instrument system following the protocol established by Affymetrix, 
Inc.  Ten μg each of RNA from the livers of 3 Hx and 3 Hx+T3 rats was used in 
the analysis.  The RNA was converted to double-stranded cDNA using an 
oligo(dT)24 primer containing a T7 RNA polymerase recognition sequence.  The 
product was transcribed into biotin-labeled cRNA using T7 RNA polymerase.  
The biotinylated cRNA was hybridized to Affymetrix GeneChip Rat Genome 230 
Plus 2.0 arrays which detects about 28,000 genes.  Multiple oligos are used for 
each gene with the data averaged.  Scanned chip images were analyzed using 
GeneChip algorithms.  
   
Real Time PCR.  To validate the microarray results, we assessed the expression 
of a subset of genes using real-time PCR.  RNA was DNAse treated using the 
TURBO DNA-Free Kit (Ambion, Austin, TX).  cDNA was prepared using the 
Reverse Transcription System (Promega) per the manufacturer’s protocol.  
Primer sequences used are listed in Table 4.  mRNA was quantified under the 
following reaction conditions: 95oC for 5 minutes, followed by 40 cycle of 95oC for 
15 seconds, 61oC for 1 minute and melt curve 55oC + 0.5oC each 10 seconds, x 
80.  All samples were run in duplicate on a Bio-Rad Chromo4 DNAEngine 
thermal cycler using SYBR green chemistry. Relative mRNA was calculated as a 
function of the internal control 18s using  Ct. 
 
Macrophage Efflux Studies.  Efflux studies were performed by the lab of George 
Rothblat (Children’s Hospital of Philadelphia, PA) as previously described (115).  
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Briefly, J774 macrophage cells or BHK cells were obtained from Dr. Jack Oram, 
University of Washington School of Medicine.  Cells were grown in 10% FBS-
DMEM in the presence of antibiotics.  Cells were radiolabeled in 2.5% FBS-
DMEM containing 1μci/ml 3H-cholesterol and 2mg, 113-818, an ACAT inhibitor 
using 0.5 ml per well.  J774 control cells and J774 cells expressing ABCA1 were 
treated with 0.3mM cpt-cAMP for 16-18 hours to upregulate ABCA1.  BHK cells 
were treated with 10 nM mifepristone for 16-18 hours to upregulate ABCG1.  All 
efflux medium was prepared using serum from Hx rats treated ±T3 diluted to 2% 
in DMEM-HEPES. 
 
2D-DIGE.  Two dimensional differential in-gel electrophoresis was performed by 
Applied Biomics (Hayward, CA).  Briefly, equal volumes of serum from 3 Hx rats 
or 3 Hx + T3 rats was combined to form a pool for each treatment.  A pool of 
serum from 2 normal rats was included as a control.  Each pool was fluorescently 
labeled with different CyDye (red, yellow, blue) for downstream visualization.  
The samples were run on first dimension isoelectric focusing and second 
dimension SDS-PAGE.  Differentially expressed proteins were quantified, cut out, 
and subjected to in-gel trypsin digestion followed by protein identification by 
MALDI-TOF mass spectrometry.   
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Table 4.  Real-time PCR Primers 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
 
Hepatic ApoA-I and ApoA-IV Gene Expression are Induced by Thyroid Hormone 
We performed a microarray analysis on liver RNA isolated from Hx rats 
treated ± T3 in order to determine the role of thyroid hormone on hepatic genes 
involved in cholesterol metabolism.  Table 5 shows a list of genes that were 
found to positively or negatively respond to T3 treatment.  The cholesterol 
transporter ABCG5 and apolipoprotein A-IV showed the greatest T3 activation, 
20-fold and 18-fold respectively.  Phospholipase A2 showed the greatest 
decrease at 142-fold less in response to T3.  These results were validated by 
real-time PCR analysis (Fig. 14).  ApoA-IV was induced approximately 60-fold 
and ABCG5 50-fold.  Additionally, we quantified the induction of ApoA-I and 
Target Sequence (5’3’) 
  
AAA CTC ACC CAG CAG CAG TTT GTG 
ABCA1 
AAG ACC AGG GCG ATG CAA ACA AAG 
        
AGA ACT GGT CAA CAA CCC TCC TGT 
ABCG1 
ATC AGG GAC ACC ACT TGG AAG CAA 
        
TCC ACT TTG GGC AAA CAG CTG AAC 
ApoA-I 
TCC TGT AGG CGA CCA ACA GTT GAA 
        
CTT TGC CAA CGA GCT AAA GG 
ApoA-IV 
GCT GCT TGT TTC AGG TGT TTC C 
        
TGA GCT CTT CCA CCA CTT CGA CAA 
ABCG5 
TGT CCA CCG ATG TCA AGT CCA TGT 
        
TGC CCG GGA TGA TAC AGC AGT 
ABCG8 
TTC TGC TCC ATG  GAT GAA CAG GGT 
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ABCG8 in response to T3, as they have been shown to be induced by T3.  ApoA-I 
was induced 8-fold and ABCG8 over 150-fold.  
 
Table 5. Subset of hepatic thyroid hormone 
responsive genes identified by microarray analysis. 
 
 
 
 
 
 
 
 
 
 
Serum ApoA-I and ApoA-IV Protein are Induced by Thyroid Hormone 
The induction of the hepatic mRNA of ApoA-I and ApoA-IV suggested that 
as more apolipoprotein is synthesized in the liver, additional protein would 
circulate in the bloodstream.   To measure changes in serum protein, we 
performed 2D DIGE on pooled serum samples from normal and Hx rats treated 
±T3 (Fig. 15).  Gel spots that were found to have significant changes (over 2-fold) 
in response to T3 treatment were trypsin digested and their protein identity 
determined by MALDI-TOF mass spectrometry.  The determined protein 
sequences were compared to the database and those with high confidence (95-
100%) are listed in Table 6.  Serum ApoA-I was found with 4 modifications  and 
Gene 
Fold 
Change 
ABCG5 + 20 
ApoA-IV + 18 
Malic Enzyme + 14 
ABCB1A + 8 
ABCD2 + 7 
Leptin Receptor + 6 
IRE Binding Protein 1 + 5 
ABCC5 + 4 
HMGR + 2 
LDLR + 2 
SCAP + 2 
ABCA8 - 3 
Insulin-like Growth Factor 2 BP 3 - 5 
Phospholipase A2, Group IIA - 142 
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increased 5-12–fold, depending on the modification.  These modifications appear 
to primarily affect the charge of the protein.  Serum ApoA-IV was found in only 
one form and was increased 2.4-fold by T3.  Fetuin-A, serine protesase inhibitor 
alpha 1, fibrinogen alpha subunit, and Clu protein were also increased.  
Interestingly, ApoE was decreased 1.6-6.0 fold in response to T3.      
 
 
 
 
 
 
Figure 14.  Real-time PCR Validation of Thyroid Hormone Responsive Hepatic 
Genes.  A. ABCG5, B. ABCG8, C. ApoA-I, D. ApoA-IV.  Data are reported as the 
mean ± standard error of the mean for each treatment.  Statistically significant 
differences are relative to control (n3).  * p<0.05, † p<0.10 
47 
 
 
 
 
 
 
Thyroid Hormone Promotes Macrophage Cholesterol Efflux via ABCA1 
The evidence for a role for thyroid hormone in cholesterol efflux has not 
been investigated.  Therefore, we conducted cholesterol efflux assays to 
determine if thyroid hormone could promote cholesterol efflux.  Using the J774 
murine macrophage cell line or BHK cells, efflux via the ABCA1 or ABCG1 
transporter can be measured.  Treatment with serum from Hx rats treated ±T3 
Figure 15.  2D DIGE of Rat Serum.  Serum was pooled from 3 rats 
treated ±T3 and ran on first dimension isoelectric focusing and second 
dimension SDS-PAGE.  Serum pools from Hx+T3 rats were labeled with 
red CyDye and serum pools from Hx rats was labeled with green CyDye  
The identities of the individual spots are listed in Table 6. 
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identified thyroid hormone-mediated cholesterol efflux via ABCA1 (Fig. 16).  
Thyroid hormone did not induce efflux via ABCG1. 
HDL cholesterol levels were measured and plotted relative to ABCA1 
efflux to identify if the increase in efflux was a result of an increase in total 
number of HDL particles (Fig.17).  There was no correlation between HDL and 
ABCA1 efflux, suggesting that the increase in cholesterol efflux is an effect 
independent of HDL particle number.      
 
 
 
Table 6.  List of serum proteins induced by thyroid hormone 
 
 
 
 
 
 
 
 
Spot Protein 
Fold 
Change 
12 Apolipoprotein A-I + 12.5 
5 Fetuin-A + 10.8 
44 Apolipoprotein A-I + 8.54 
14 Preproapolipoprotein A-I + 7.80 
4 Fetuin-A + 6.12 
13 Apolipoprotein A-I + 5.02 
33 Fetuin-A + 4.57 
32 Fetuin-A + 4.12 
24 Serine protease inhibitor alpha 1 + 3.61 
10 Fibrinogen alpha subunit + 3.48 
23 Clu protein + 3.29 
22 Clu protein + 2.66 
11 Apolipoprotein A-IV + 2.38 
18 Apolipoprotein E - 3.45 
21 Apolipoprotein E - 8.62 
49 
Figure 17.  ABCA1 Efflux is Not Mediated by an Increase in Serum HDL 
cholesterol.  Serum was collected from normal and hypophysectomized rats 
treated ±T3.  Normalized ABCA1 efflux was plotted relative to serum HDL 
cholesterol levels for individual serum samples. 
 
 
 
 
 
 
 
 
 
  
Figure 16.  Thyroid Hormone Increases Macrophage Cholesterol Efflux via the 
ABCAI Cholesterol Transporter.  Serum was collected from normal and 
hypophysectomized rats treated ±T3.  Relative ABCA1 efflux (A) and ABCG1 efflux 
(B) was determined as described in Material and Methods. Data are reported as the 
mean ± standard error of the mean for each treatment.  Statistically significant 
differences are relative to Hx. For all conditions, n4 and *p<0.05. 
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Discussion 
The role of thyroid hormone in cholesterol efflux was investigated in 
Sprague-Dawley hypophysectomized rats treated ±T3.  These hypothyroid rats 
show moderately increased levels of LDL cholesterol that is markedly decreased 
with thyroid hormone treatment, similar to the effects observed in humans (37, 
42).  We utilized this animal model to mimic the cholesterol transport pathways 
under thyroid hormone control in the human.  We performed microarray analysis 
on hepatic RNA from Hx rats treated ±T3 to identify thyroid hormone-responsive 
genes involved in cholesterol metabolism.  Cholesterol-related genes with the 
greatest inductions were ABCG5 and ApoA-IV.  ABCG5 functions as a 
membrane cholesterol transporter mainly in the liver and small intestine.  Though 
relevant to the entire cholesterol transport process, it is not specifically involved 
in cholesterol efflux from macrophages.  ApoA-IV is an apolipoprotein involved in 
the transport of cholesterol, predominantly as a member of HDL (113).  ApoA-IV 
has also been shown to function as an acceptor in cholesterol efflux from 
macrophages (110).   
Phospholipase A2, Group IIA (PLA2) was the only gene significantly 
down-regulated by thyroid hormone.  PLA2 is a small lipolytic enzyme that 
releases fatty acids from the second carbon of glycerol.  PLA2 has been shown 
to be up-regulated in hepatocytes in response to stress stimuli and secreted from 
liver cells (116).  More importantly, overexpression of PLA2 in mice increased the 
incidence of atherosclerotic lesions, decreased plasma HDL, and increased 
plasma LDL (117).  PLA2 has been identified in atherosclerotic lesions (118) and 
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has been suggested to aid in the transformation of macrophages into foam-cells 
by promoting macrophage LDL uptake (119, 120).  The striking reduction in this 
gene in response to thyroid hormone suggests an alternative antiatherogenic 
property of T3. 
We performed real-time PCR analysis to validate our microarray findings.  
In addition to the inductions observed in ABCG5 and ApoA-IV, we also identified 
increases in ABCG8 and ApoA-I.  Like ABCG5, ABCG8 is a membrane 
cholesterol transporter found in the liver and small intestine.  ABCG5 and ABCG8 
share a bidirectional promoter that is analyzed in the Chapter 4 of this report.  
ApoA-I is the major apolipoprotein component of HDL.  We hypothesized that the 
increase in hepatic ApoA-IV and ApoA-I led to an increase in cholesterol loading 
of HDL particles via efflux from the ABCA1 or ABCG1 transporters. 
We analyzed the rat serum proteins differentially regulated by T3 using 
2D-DIGE and downstream mass spectrometric protein analysis.  The cholesterol 
transport proteins with the greatest increases in the T3-treated serum were ApoA-
I and ApoA-IV.  Depending on the posttranslational modification, an increase of 
up to 12.5-fold was observed for ApoA-I and 2.4 for ApoA-IV.  Since the total 
amount of serum HDL is not increased in response to T3, it may be that the total 
amount of ApoA-I or ApoA-IV per HDL particle increases.  An increase in lipid-
accepting apolipoprotein would facilitate the loading of additional cholesterol onto 
HDL particles, as treatment with ApoA-I mimetic peptides was able to increase 
cholesterol efflux (108).  Serum ApoE, a component of chylomicrons and IDL and 
some HDL, was decreased in response to T3 treatment.  These results correlate 
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well with a previous study that demonstrated an increase in serum ApoE in 
hypothyroid rats (121).  The decrease in ApoE may signify the conversion of 
more HDL particles to ApoA-I-rich particles capable of accepting cholesterol and 
the decrease in a need for additional ApoE particles. 
Finally, the effects of thyroid hormone on cholesterol efflux were examined 
in two cell lines capable of inducing cholesterol efflux.  Cholesterol efflux was 
increased approximately 2-fold in cells expressing the ABCA1 transporter.  There 
was no increase in efflux in cells expressing the ABCG1 transporter.  This is 
consistent with previous reports that suggest an initial direct interaction between 
lipid-poor ApoA-I and ABCA1 (96) that results in the transfer of cholesterol to 
ApoA-I, followed by further lipidation via ABCG1 (103). 
We have provided the first evidence of thyroid hormone induced 
macrophage cholesterol efflux via the ABCA1 transporter.  Based on an analysis 
of serum protein, is seems that an increase in the amounts of ApoA-I and ApoA-
IV serum protein in the T3-treated serum in responsible for the additional 
cholesterol accepting capacity of the associated lipoproteins.        
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Chapter 4 
Analysis of the ABCG8 Promoter 
Introduction 
 
ABCG5 and ABCG8 (ABCG5/G8) are membrane transporters of the ATP-
binding cassette transporter superfamily.  ABCG5/G8 are half transporters that 
form heterodimers to become functional (122).  They are expressed primarily in 
the small intestine and liver and function to limit the uptake of dietary cholesterol 
from the intestine and promote biliary secretion of cholesterol from the liver (123, 
124).  Mutations in these genes have been well-documented to cause 
sitosterolemia (15, 125, 126).  This disease is characterized by high levels of 
plasma plant sterols and increased levels of plasma cholesterol.  ABCG5/G8 are 
recognized as the main pathway for sterol secretion into the bile and thus play an 
important role in cholesterol transport (127). 
 ABCG5 and ABCG8 are two distinct that genes that lie in a head-to-head 
orientation and are under the control of a shared, bidirectional promoter (128).  
We have minimal knowledge of the regulation of the shared promoter, however 
liver receptor homologue 1 (LRH-1), nuclear factor 4 alpha (NF4), and GATA 
have been shown to bind to this promoter (129, 130).  There have been no 
reports on the identification of hormone response elements.  
ABCG5/G8 are regulated by thyroid hormone.  A study of 
hypophysectomized rats found that intestinal absorption of cholesterol was 
doubled and could be normalized with thyroid hormone treatment.  Also, hepatic 
54 
secretion of cholesterol and ABCG5/G8 expression are strongly stimulated in 
hypophysectomized rats during treatment with thyroid hormone (33).  We aimed 
to identify the thyroid hormone response elements in the shared ABCG5/G8 
promoter using EMSAs and in vivo electroporation.  
 
Materials and Methods 
 
Electrophoretic Mobility Shift Assay.  EMSAs were performed as described in 
Materials and Methods in Chapter 2.  Additional probes are listed in Table 7. For 
antibody supershift experiments, binding reactions were incubated with 3 μg of 
antisera for 30 minutes prior to the addition of probe.  The antibodies were 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA): TR-1 (sc-772x), 
TR1 (sc-772x), RXR (sc-553x) 
 
Plasmid Construction. The rat ABCG8 promoter was amplified to -444/+123 from 
a genomic BAC clone (CH230-263N2) from the rat genome using the Expand 
Long Template PCR System (Roche).  The -444/+123 promoter segment in 
pGL3-Basic (Promega, Madison, WI) was obtained using the primer sequences: 
forward 5’-GAA CCG GGT ACC ATA GGG TGG GAA GCC TA-3’ and reverse 5’- 
GAA CCG GCT AGC GAC CTG CGG TGT TGT-3’.  This PCR product contains 
a KpnI site on the forward primer and NheI site on the reverse primer for cloning 
into pGL3-Basic.  All clones were confirmed by restriction analysis and DNA 
sequencing at the Moffitt Molecular Biology Core Facility (Tampa, FL). 
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Experimental Animals and In Vivo Electroporation were performed as described 
under Materials and Methods in Chapter 2 with the ABCG8 promoter-luciferase 
plasmid. 
 
Table 7.  ABCG8 Promoter EMSA Probes 
Target Sequence (5’3’) 
  
ACAGAGGGCAGGTGATGGACCAGCCAAGGAA 
1 
CGATTTCCTTGGCTGGTCCATCACCTGCCCTCTGT 
        
TAGACAGGCAGCCCAAAGCCCACAGGCCCAC 
2 
CGATGTGGGCCTGTGGGCTTTGGGCTGCCTGTCTA 
        
GCTGTGGGGTCCCCTTACCTGACGCTGAAGGAC 
3 
CGATGTCCTTCAGCGTCAGGTAAGGGGACCCCACAGC 
        
CGCTGAAGGACACATTCAGGACACCTAA 
4 
CGATTTAGGTGTCCTGAATGTGTCCTTCAGCG 
        
TGAATCCTCTGGTGTCCTGTCTGGCTTCA 
5 
CGATTGAAGCCAGACAGGACACCAGAGGATTCA 
        
TTTAGCCAGAGTGTCCTTATCTCGACAAT 
6 
CGATATTGTCGAGATAAGGACACTCTGGCTAAA 
        
CAACACCGCACCTCATGGCTGAGAAGACC 
7 
CGATGGTCTTCTCAGCCATGACCTGCGGTGTTG 
        
CAAGATGAAACTGACCTTTCTTTCCTAC 
8 
CGATGTAGGAAAGAAAGGTCAGTTTCATCTTG 
        
CACAGAATTAGTCCTAGTTCACCAC 
9 
CGATGTGGTGAACTAGGACTAATTCTGTG 
        
AGGACGTTGGGGTTAGGGGAGGACAGTG Malic Enzyme 
TRE CGATCACTGTCCTCCCCTAACCCCAACGTCCT 
        
GCTGTGGGGTCCCCTTACCTGACGCTGAAGGACACATT
CAGGGACACCTAA 
-420/-371 Wt 
CGATTTAGGTGTCCTGAATGTGTCCTTCAGCGTCAGGTA
AGGGGACCCCACAGC 
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Table 8.  ABCG8 Promoter Mutant EMSA Probes 
Target Sequence (5’3’) 
TCTGTGGGGTCCCCTTACCTGACGCTGAAGGACACATTCAGGACACCTAA 1 
CGATTTAGGTGTCCTGAATGTGTCCTTCAGCGTCAGGTAAGGGGACCCCACAGA 
        
GATGTGGGGTCCCCTTACCTGACGCTGAAGGACACATTCAGGACACCTAA 
2 
CGATTTAGGTGTCCTGAATGTGTCCTTCAGCGTCAGGTAAGGGGACCCCACATC 
        
GCGGTGGGGTCCCCTTACCTGACGCTGAAGGACACATTCAGGACACCTAA 
3 
CGATTTAGGTGTCCTGAATGTGTCCTTCAGCGTCAGGTAAGGGGACCCCACCGC 
        
GCTTTGGGGTCCCCTTACCTGACGCTGAAGGACACATTCAGGACACCTAA 
4 
CGATTTAGGTGTCCTGAATGTGTCCTTCAGCGTCAGGTAAGGGGACCCCAAAGC 
        
GCTGGGGGGTCCCCTTACCTGACGCTGAAGGACACATTCAGGACACCTAA 
5 
CGATTTAGGTGTCCTGAATGTGTCCTTCAGCGTCAGGTAAGGGGACCCCCCAGC 
        
GCTGTTGGGTCCCCTTACCTGACGCTGAAGGACACATTCAGGACACCTAA 
6 
CGATTTAGGTGTCCTGAATGTGTCCTTCAGCGTCAGGTAAGGGGACCCAACAGC 
        
GCTGTGTGGTCCCCTTACCTGACGCTGAAGGACACATTCAGGACACCTAA 
7 
CGATTTAGGTGTCCTGAATGTGTCCTTCAGCGTCAGGTAAGGGGACCACACAGC 
        
GCTGTGGTGTCCCCTTACCTGACGCTGAAGGACACATTCAGGACACCTAA 
8 
CGATTTAGGTGTCCTGAATGTGTCCTTCAGCGTCAGGTAAGGGGACACCACAGC 
        
GCTGTGGGTTCCCCTTACCTGACGCTGAAGGACACATTCAGGACACCTAA 
9 
CGATTTAGGTGTCCTGAATGTGTCCTTCAGCGTCAGGTAAGGGGAACCCACAGC 
        
GCTGTGGGGGCCCCTTACCTGACGCTGAAGGACACATTCAGGACACCTAA 
10 
CGATTTAGGTGTCCTGAATGTGTCCTTCAGCGTCAGGTAAGGGGCCCCCACAGC 
        
GCTGTGGGGTACCCTTACCTGACGCTGAAGGACACATTCAGGACACCTAA 
11 
CGATTTAGGTGTCCTGAATGTGTCCTTCAGCGTCAGGTAAGGGTACCCCACAGC 
        
GCTGTGGGGTCACCTTACCTGACGCTGAAGGACACATTCAGGACACCTAA 
12 
CGATTTAGGTGTCCTGAATGTGTCCTTCAGCGTCAGGTAAGGTGACCCCACAGC 
        
GCTGTGGGGTCCACTTACCTGACGCTGAAGGACACATTCAGGACACCTAA 
13 
CGATTTAGGTGTCCTGAATGTGTCCTTCAGCGTCAGGTAAGTGGACCCCACAGC 
        
GCTGTGGGGTCCCATTACCTGACGCTGAAGGACACATTCAGGACACCTAA 
14 
CGATTTAGGTGTCCTGAATGTGTCCTTCAGCGTCAGGTAATGGGACCCCACAGC 
        
GCTGTGGGGTCCCCGTACCTGACGCTGAAGGACACATTCAGGACACCTAA 
15 
CGATTTAGGTGTCCTGAATGTGTCCTTCAGCGTCAGGTACGGGGACCCCACAGC 
        
GCTGTGGGGTCCCCTGACCTGACGCTGAAGGACACATTCAGGACACCTAA 
16 
CGATTTAGGTGTCCTGAATGTGTCCTTCAGCGTCAGGTCAGGGGACCCCACAGC 
        
GCTGTGGGGTCCCCTTCCCTGACGCTGAAGGACACATTCAGGACACCTAA 
17 
CGATTTAGGTGTCCTGAATGTGTCCTTCAGCGTCAGGGAAGGGGACCCCACAGC 
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Table 8 (Continued).  ABCG8 Promoter Mutant EMSA Probes 
Target Sequence (5’3’) 
GCTGTGGGGTCCCCTTAACTGACGCTGAAGGACACATTCAGGACACCTAA 
18 
CGATTTAGGTGTCCTGAATGTGTCCTTCAGCGTCAGTTAAGGGGACCCCACAGC 
        
GCTGTGGGGTCCCCTTACATGACGCTGAAGGACACATTCAGGACACCTAA 
19 
CGATTTAGGTGTCCTGAATGTGTCCTTCAGCGTCATGTAAGGGGACCCCACAGC 
        
GCTGTGGGGTCCCCTTACCGGACGCTGAAGGACACATTCAGGACACCTAA 
20 
CGATTTAGGTGTCCTGAATGTGTCCTTCAGCGTCCGGTAAGGGGACCCCACAGC 
        
GCTGTGGGGTCCCCTTACCTTACGCTGAAGGACACATTCAGGACACCTAA 
21 
CGATTTAGGTGTCCTGAATGTGTCCTTCAGCGTAAGGTAAGGGGACCCCACAGC 
        
GCTGTGGGGTCCCCTTACCTGCCGCTGAAGGACACATTCAGGACACCTAA 
22 
CGATTTAGGTGTCCTGAATGTGTCCTTCAGCGGCAGGTAAGGGGACCCCACAGC 
        
GCTGTGGGGTCCCCTTACCTGAAGCTGAAGGACACATTCAGGACACCTAA 
23 
CGATTTAGGTGTCCTGAATGTGTCCTTCAGCTTCAGGTAAGGGGACCCCACAGC 
        
GCTGTGGGGTCCCCTTACCTGACTCTGAAGGACACATTCAGGACACCTAA 
24 
CGATTTAGGTGTCCTGAATGTGTCCTTCAGAGTCAGGTAAGGGGACCCCACAGC 
        
GCTGTGGGGTCCCCTTACCTGACGATGAAGGACACATTCAGGACACCTAA 
25 
CGATTTAGGTGTCCTGAATGTGTCCTTCATCGTCAGGTAAGGGGACCCCACAGC 
        
GCTGTGGGGTCCCCTTACCTGACGCGGAAGGACACATTCAGGACACCTAA 
26 
CGATTTAGGTGTCCTGAATGTGTCCTTCCGCGTCAGGTAAGGGGACCCCACAGC 
        
GCTGTGGGGTCCCCTTACCTGACGCTTAAGGACACATTCAGGACACCTAA 
27 
CGATTTAGGTGTCCTGAATGTGTCCTTAAGCGTCAGGTAAGGGGACCCCACAGC 
        
GCTGTGGGGTCCCCTTACCTGACGCTGCAGGACACATTCAGGACACCTAA 
28 
CGATTTAGGTGTCCTGAATGTGTCCTGCAGCGTCAGGTAAGGGGACCCCACAGC 
        
GCTGTGGGGTCCCCTTACCTGACGCTGACGGACACATTCAGGACACCTAA 
29 
CGATTTAGGTGTCCTGAATGTGTCCGTCAGCGTCAGGTAAGGGGACCCCACAGC 
        
GCTGTGGGGTCCCCTTACCTGACGCTGAATGACACATTCAGGACACCTAA 
30 
CGATTTAGGTGTCCTGAATGTGTCATTCAGCGTCAGGTAAGGGGACCCCACAGC 
        
GCTGTGGGGTCCCCTTACCTGACGCTGAAGTACACATTCAGGACACCTAA 
31 
CGATTTAGGTGTCCTGAATGTGTACTTCAGCGTCAGGTAAGGGGACCCCACAGC 
        
GCTGTGGGGTCCCCTTACCTGACGCTGAAGGCCACATTCAGGACACCTAA 
32 
CGATTTAGGTGTCCTGAATGTGGCCTTCAGCGTCAGGTAAGGGGACCCCACAGC 
        
GCTGTGGGGTCCCCTTACCTGACGCTGAAGGAAACATTCAGGACACCTAA 
33 
CGATTTAGGTGTCCTGAATGTTTCCTTCAGCGTCAGGTAAGGGGACCCCACAGC 
        
GCTGTGGGGTCCCCTTACCTGACGCTGAAGGACCCATTCAGGACACCTAA 
34 
CGATTTAGGTGTCCTGAATGGGTCCTTCAGCGTCAGGTAAGGGGACCCCACAGC 
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Table 8 (Continued).  ABCG8 Promoter Mutant EMSA Probes 
 
Target Sequence (5’3’) 
GCTGTGGGGTCCCCTTACCTGACGCTGAAGGACAAATTCAGGACACCTAA 
35 
CGATTTAGGTGTCCTGAATTTGTCCTTCAGCGTCAGGTAAGGGGACCCCACAGC 
        
GCTGTGGGGTCCCCTTACCTGACGCTGAAGGACACCTTCAGGACACCTAA 
36 
CGATTTAGGTGTCCTGAAGGTGTCCTTCAGCGTCAGGTAAGGGGACCCCACAGC 
        
GCTGTGGGGTCCCCTTACCTGACGCTGAAGGACACAGTCAGGACACCTAA 
37 
CGATTTAGGTGTCCTGACTGTGTCCTTCAGCGTCAGGTAAGGGGACCCCACAGC 
        
GCTGTGGGGTCCCCTTACCTGACGCTGAAGGACACATGCAGGACACCTAA 
38 
CGATTTAGGTGTCCTGCATGTGTCCTTCAGCGTCAGGTAAGGGGACCCCACAGC 
        
GCTGTGGGGTCCCCTTACCTGACGCTGAAGGACACATTAAGGACACCTAA 
39 
CGATTTAGGTGTCCTTAATGTGTCCTTCAGCGTCAGGTAAGGGGACCCCACAGC 
        
GCTGTGGGGTCCCCTTACCTGACGCTGAAGGACACATTCCGGACACCTAA 
40 
CGATTTAGGTGTCCGGAATGTGTCCTTCAGCGTCAGGTAAGGGGACCCCACAGC 
        
GCTGTGGGGTCCCCTTACCTGACGCTGAAGGACACATTCATGACACCTAA 
41 
CGATTTAGGTGTCATGAATGTGTCCTTCAGCGTCAGGTAAGGGGACCCCACAGC 
        
GCTGTGGGGTCCCCTTACCTGACGCTGAAGGACACATTCAGTACACCTAA 
42 
CGATTTAGGTGTACTGAATGTGTCCTTCAGCGTCAGGTAAGGGGACCCCACAGC 
        
GCTGTGGGGTCCCCTTACCTGACGCTGAAGGACACATTCAGGCCACCTAA 
43 
CGATTTAGGTGGCCTGAATGTGTCCTTCAGCGTCAGGTAAGGGGACCCCACAGC 
        
GCTGTGGGGTCCCCTTACCTGACGCTGAAGGACACATTCAGGAAACCTAA 
44 
CGATTTAGGTTTCCTGAATGTGTCCTTCAGCGTCAGGTAAGGGGACCCCACAGC 
        
GCTGTGGGGTCCCCTTACCTGACGCTGAAGGACACATTCAGGACCCCTAA 
45 
CGATTTAGGGGTCCTGAATGTGTCCTTCAGCGTCAGGTAAGGGGACCCCACAGC 
        
GCTGTGGGGTCCCCTTACCTGACGCTGAAGGACACATTCAGGACAACTAA 
46 
CGATTTAGTTGTCCTGAATGTGTCCTTCAGCGTCAGGTAAGGGGACCCCACAGC 
        
GCTGTGGGGTCCCCTTACCTGACGCTGAAGGACACATTCAGGACACATAA 
47 
CGATTTATGTGTCCTGAATGTGTCCTTCAGCGTCAGGTAAGGGGACCCCACAGC 
        
GCTGTGGGGTCCCCTTACCTGACGCTGAAGGACACATTCAGGACACCGAA 
48 
CGATTTCGGTGTCCTGAATGTGTCCTTCAGCGTCAGGTAAGGGGACCCCACAGC 
        
GCTGTGGGGTCCCCTTACCTGACGCTGAAGGACACATTCAGGACACCTCA 
49 
CGATTGAGGTGTCCTGAATGTGTCCTTCAGCGTCAGGTAAGGGGACCCCACAGC 
        
GCTGTGGGGTCCCCTTACCTGACGCTGAAGGACACATTCAGGACACCTAC 
50 
CGATGTAGGTGTCCTGAATGTGTCCTTCAGCGTCAGGTAAGGGGACCCCACAGC 
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Results 
EMSA Analysis of the ABCG8 Promoter 
Due to the large induction of ABCG5/G8 expression in response to thyroid 
hormone, we analyzed the shared promoter for potential thyroid hormone 
response elements (TREs).  We identified 9 elements that could function as 
TREs based on the canonical direct repeat-4 (DR-4) sequence: 
AGGTCAnnnnAGGTCA.  We used nuclear extract prepared from normal rats to 
perform EMSA antibody supershift experiments with antisera to TR-1.  The TR 
antibody used in these experiments recognizes TR-1 and was the only 
functional antibody identified for antibody supershift experiments.  Radiolabeled 
probes corresponding to the potential TREs in the ABCG8 promoter were 
incubated with nuclear extract in the binding reactions labeled in Figure 18.  A 
probe to the known malic enzyme TRE served as a positive control.  The probes 
corresponding to the -420/-388 and -398/-371 promoter regions showed strong 
shifted bands in the presence of TR-1 antibody.  The probes corresponding to -
233/-205 and -88/-60 promoter regions showed weakly shifted bands in the 
presence of TR-1 antibody. 
 
TR-1 and RXR Bind the ABCG8 Promoter 
The binding reactions that resulted in antibody supershifts were then 
incubated with antibody to RXR-, which heterodimerizes with TR-1 in 
activation of thyroid hormone responsive genes. The probes corresponding to the 
-420/-388 and -398/-371 promoter regions showed strong shifted bands in the 
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presence of either TR-1 or RXR or a combination of both (Fig. 19).  The 
probes corresponding to -233/-205 and -88/-60 promoter regions did not produce 
strong shifted bands in any of the antibody treatments. 
 
 
 
 
 
 
 
 
 
Identification of a TRE at -392/-376 
In an effort to identify the nucleotides in the -420/-371 promoter region to 
which TR1 and RXR bind, we performed EMSAs with a radiolabeled probe to 
the -420/-371 promoter region.  The labeled Wt probe was incubated in a binding 
reaction with normal rat liver nuclear extract.  An unlabeled double-stranded 
oligonucleotide corresponding to the exact sequence of the Wt with the exception 
Figure 18.  EMSA Analysis of the ABCG8 Promoter.  Probes corresponding to 
the identified promoter regions were incubated with 2 μg of pooled nuclear extract 
prepared from the livers of normal rats.  Three μg of TR antibody, which positively 
recognizes TR-1, or a negative control TR-1 antibody was added to each binding 
reaction to obtain a supershift of the protein-probe complex.  The malic enzyme 
TRE was used as a positive control.  
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of single nucleotide substitutions was added in 50x molar excess relative to the 
radiolabeled probe in the remaining lanes (Fig. 20).  The sequence at the top of 
the figure is the wild type promoter sequence, with an arrow highlighting the 
nucleotide substitution in each lane.  The Wt band in Figure 20 can be efficiently 
competed away with the cold wild-type competitor (4th lane).  The mutants that 
were unable to compete away the wild-type binding represent the sequence at -
392/-376: AGGACAcattcAGGACA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19.  TR-1 and RXR  Bind the ABCG8 Promoter.  Probes corresponding 
to the identified promoter regions were incubated with 2 μg of pooled nuclear 
extract prepared from the livers of normal rats.  Three μg of TR antibody, which 
positively recognizes TR-1, or RXR antibody, or a combination of both 
antibodies, was added to each binding reaction to obtain a supershift of the protein-
probe complex.    
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The -444/+123 ABCG8 Promoter Plasmid is not Functional by in vivo Electroporation. 
The promoter region corresponding to the proximal promoter out to -444 
was cloned into the pGL3-Basic luciferase plasmid backbone to evaluate the 
thyroid hormone response by luciferase assay.  The plasmid was electroporated 
in the livers of normal rats and Hx rats treated ±T3 to determine if this region of 
the promoter could induce a thyroid hormone response.  Unfortunately, this 
plasmid was not functional and did not produce luciferase activity over 
background (Fig 21).   
Figure 20.  EMSA Analysis of the -420/-371 ABCG8 Promoter Region.  EMSA 
using 50x competitor probes to identify nucleotides that are necessary for binding to 
occur to the -420/-371 region.  The wild-type promoter sequence is listed on top 
with an arrow pointing to the point mutation in the competitor probe. 
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Discussion 
 In hypophysectomized (Hx) rats, intestinal absorption of cholesterol is 
doubled, and treatment with T3 normalizes this effect (33).  The ATP-Binding 
Cassette (ABC) transporters ABCG5 and ABCG8 function as half-transporters in 
the intestine and liver to limit intestinal absorption and promote biliary excretion 
of cholesterol, respectively (123, 124).  Hepatic expression of both genes is 
diminished in hypophysectomized rats, but is greatly induced (up to 100-fold) by 
subsequent treatment with thyroid hormone.  This suggests that ABCG5/8 
function to mediate thyroid hormone-dependent biliary secretion of cholesterol.  
Figure 21.  The -444/+123 ABCG8 Promoter Plasmid is not Functional by in 
vivo Electroporation.  An ABCG8 promoter construct inclusive of the -444/+123 
region was electroporated into the livers of hypophysectomized rats treated ±T3.  
Data are reported as the mean ± standard error of the mean for each promoter 
construct. 
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Due to the drastic induction of these genes by T3, the shared promoter of these 
genes was analyzed for thyroid hormone response elements (TREs).  The 
intergenic region, including the bidirectional promoter, is heavily conserved (128) 
among several species.  Multiple sequence alignment and transcription factor 
prediction algorithms were applied to the sequences to identify potential TREs.  
Nine regions of high conservation and high probability of TREs were identified.  
These sequences were analyzed for TR-1 binding ability by EMSA.  The -420/-
371 ABCG8 downstream region showed the strongest shifted bands in the 
presence of TR-1 antibody.  Within this region, the element 
AGGACAcattcAGGACA was shown to be necessary for binding to occur.  
Promoter luciferase plasmids were prepared to include this region (-444/+123) 
and introduced into the livers of Hx rats treated ±T3 to determine if a thyroid 
hormone response could be measure by luciferase activity.  Unfortunately, the 
prepared plasmid was not functional and produced no measurable luciferase 
assay.  Consequently, there was no observed T3 response in this plasmid. 
 Additional investigation and cloning of the rat ABCG8 promoter sequence 
into the pGL3-Basic luciferase backbone did not provide a functional plasmid.  A 
reporter gene inclusive of a 358bp fragment of the murine ABCG5/G8 promoter 
was also not functional as a promoter plasmid (131).  Cloning of the 
corresponding human sequence produced a functional promoter activity 
response (128).  We evaluated the possibility of a reading frame shift in the 
cloned sequence, but did not find any alterations that would have affected 
transcription initiation.  It is unclear if this short sequence is incapable of 
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functioning as a minimal promoter or if other transcriptional mechanisms are 
impaired.   
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Chapter 5 
Final Conclusions and Discussion 
Thyroid hormone exerts multiple and critical roles in cholesterol 
metabolism.  In general, thyroid hormone has atheroprotective effects that 
include decreased circulating LDL cholesterol, decreased absorption of dietary 
cholesterol, and increased biliary secretion of cholesterol (Fig. 22).  These effects 
are the result of thyroid hormone’s direct regulation of a number of hepatic and 
intestinal genes involved in cholesterol metabolism.  We examined the role of 
thyroid hormone in three areas of cholesterol metabolism: i) hepatic cholesterol 
synthesis under the control of HMG-CoA reductase, ii) macrophage cholesterol 
efflux, and iii) ABCG5/G8-mediated biliary secretion of cholesterol. 
The activation of HMGR by thyroid hormone has been well documented.  
Throughout previous studies, however, the mechanism facilitating this activation 
has been largely overlooked.  We identified USF-2, SREBP-2, and NF-Y as 
necessary factors in this activation using in vivo techniques.  siRNA 
coelectroporation studies demonstrated the necessity of these factors in thyroid 
hormone induction of HMGR promoter activity.  Quantitative ChIP analyses 
suggested that while SREBP-2 and NF-Y are necessary factors for activation, the 
relative amounts of promoter binding does not change in response to thyroid 
hormone.  However, thyroid hormone was shown to increase the relative binding 
of USF-2 4-fold.  We propose that in the absence of thyroid hormone, USF-2 
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does not bind the HMGR promoter.  Upon thyroid hormone treatment, a dimer or 
tetramer of USF-2 is recruited to the promoter thus activating HMGR transcription 
(Fig. 23). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22.  Combined Actions of Thyroid Hormone on Cholesterol Metabolism.  
The atheroprotective effects of thyroid hormone include increased biliary secretion of 
cholesterol, decreased intestinal absorption of cholesterol, and increased hepatic 
uptake of cholesterol resulting in lower LDL cholesterol levels.   
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The ability to increase cholesterol efflux presents an intriguing treatment 
for atherosclerosis.  Lipid-poor ApoA-I particles are able to remove cholesterol 
from atherogenic cholesterol-laden macrophages to be transported to the liver for 
excretion.  A model of selective delipidation of plasma HDL in primates 
demonstrated decreased atherosclerosis in the presence of lipid-poor ApoA-I 
(132).  We determined that hepatic ApoA-I and ApoA-IV mRNA are increased by 
thyroid hormone.  This hepatic induction translates to increased serum ApoA-I 
and ApoA-IV.  Correspondingly, macrophage cholesterol efflux is induced via the 
Figure 23.  Proposed Model of HMGR Promoter.  In the absence of thyroid 
hormone USF-2 does not bind the HMGR promoter (top panel).  Upon treatment with 
thyroid hormone, USF-2 dimerizes and is recruited to the HMGR promoter, thus 
stimulating transcription (bottom panel). 
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ABCA1 transporter and not the ABCG1 transporter in response to thyroid 
hormone.  We propose that the increase in serum ApoA-I and ApoA-IV facilitates 
the increased cholesterol efflux from macrophages (Fig. 24).  These data provide 
further insight into the mechanisms of thyroid hormone’s atheroprotective effects 
and potentially provide a therapeutic target for treating atherosclerosis.  The 
Metabasis TR agonist that targets the liver (MB07811) results in a reduction in 
serum cholesterol and an induction of hepatic T3-responsive genes (39).  
Unfortunately, the effects of the agonist on hepatic ApoA-I and ApoA-IV were not 
examined.  It would be interesting, and perhaps beneficial, to determine if a TR 
agonist is able to increase serum ApoA-I and ApoA-IV with a downstream 
induction of cholesterol efflux.  The area of thyroid hormone-mediated cholesterol 
efflux is a novel field of study that has the potential to provide success in treating 
atherosclerosis.   
Thyroid hormone regulation of biliary cholesterol secretion provides 
another therapeutic target for hypercholesterolemia.  The hepatic ABCG5/G8 
cholesterol transporters are activated by thyroid hormone.  Using EMSAs, we 
identified a TR binding site at -392/-376 of the ABCG8 promoter.  This TR 
binding site presents a target for the TR agonist class of therapeutics.  It would 
be advantageous to the field of hypercholesterolemia research to ascertain if the 
liver-specific TR agonist, MB07811, activates ABCG5/G8.  Upregulation of 
ABCG5/G8 should lead to increased biliary secretion of cholesterol, as was 
identified in the hypophysectomized rat treated with thyroid hormone (33).   
 
70 
 
 
 
 
 
 
 
 
 
 
 
 
The future role of thyroid hormone in treating hypercholesterolemia and 
associated diseases may lie in the design of liver-specific TR agonists or other 
factors involved in the mechanism of thyroid hormone activation of hepatic 
genes.  We hope that these present data will provide the research community 
Figure 24.  Thyroid Hormone Induces Cholesterol Efflux.  Apolipoprotein 
loading in the absence (upper left grey) and presence (lower right white) of thyroid 
hormone.  In the presence of T3, 1) Hepatic ApoA-I and ApoA-IV are induced 
leading to increased levels of serum ApoA-I and ApoA-IV; 2) Lipid-poor HDL 
particles have a greater capacity to accumulate cholesterol from macrophages via 
the ABCA1 transporter; 3) Lipid-rich HDL completes the reverse cholesterol 
transport process by delivering cholesterol to the liver via the LDL receptor 
pathway.     
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with additional incentive to develop useful T3 analogs to treat 
hypercholesterolemia.     
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